Shaikh Safiya Imtiaz, Kumari R Vasantha, Hegade Ganapati, Marutheesh M
Department of Anaesthesiology, Karnataka Institute of Medical Sciences, Hubli, Karnataka, India.
Anesth Essays Res. 2017 Jan-Mar;11(1):10-16. doi: 10.4103/0259-1162.179313.
Anticoagulants remain the primary strategy for the prevention and treatment of thrombosis. Unfractionated heparin, low molecular weight heparin (LMWH), fondaparinux, and warfarin have been studied and employed extensively with direct thrombin inhibitors typically reserved for patients with complications or those requiring interventions. Novel oral anticoagulants have emerged from clinical development and are expected to replace older agents with their ease to use and more favorable pharmacodynamic profiles. Increasingly, anesthesiologists are being requested to anesthetize patients who are on some form of anticoagulants and hence it is important to have sound understanding of pharmacology, dosing, monitoring, and toxicity of anticoagulants. We searched the online databases including PubMed Central, Cochrane, and Google Scholar using anticoagulants, perioperative management, anesthetic considerations, and LMWH as keywords for the articles published between 1994 and 2015 while writing this review. In this article, we will review the different classes of anticoagulants and how to manage them in the perioperative settings.
抗凝剂仍然是预防和治疗血栓形成的主要策略。普通肝素、低分子量肝素(LMWH)、磺达肝癸钠和华法林已得到广泛研究和应用,直接凝血酶抑制剂通常用于有并发症的患者或需要干预的患者。新型口服抗凝剂已进入临床应用阶段,因其使用方便且药效学特性更佳,有望取代传统药物。越来越多的麻醉医生被要求为正在使用某种抗凝剂的患者实施麻醉,因此,深入了解抗凝剂的药理学、剂量、监测和毒性非常重要。在撰写本综述时,我们使用抗凝剂、围手术期管理、麻醉注意事项和低分子量肝素作为关键词,检索了包括PubMed Central、Cochrane和谷歌学术在内的在线数据库,以查找1994年至2015年间发表的文章。在本文中,我们将综述不同类别的抗凝剂以及如何在围手术期进行管理。